Ogier

Ogier advises Cure Genetics on USD\$60 million Series B funding

Deals - 05/01/2022

Ogier's corporate team has acted as British Virgin Islands and Cayman Islands counsel to Suzhou Cure Genetics Co Ltd (Cure Genetics) for its USD\$60 million Series B fund raising on 5 January 2022.

The investors in this round of funding included Advantech Capital, Oriza Holdings, Blue Ocean Capital and Qiming Ventures Partners, with China Renaissance as the exclusive financial advisor.

Cure Genetics, headquartered in Suzhou, China, is a biotechnology company specialising in developing gene therapy. The funding raised would enable Cure Genetics to advance its clinical development of therapeutic pipelines for hematologic and solid tumours, and to enhance international collaborations based in its innovative AAV serotype screening platform and gene editing products.

The Ogier team, based in Hong Kong, was led by partner Cecilia Li with support from the firm's global head of Corporate, Nathan Powell, and paralegal Vicky Wu.

About Ogier

Ogier is a professional services firm with the knowledge and expertise to handle the most demanding and complex transactions and provide expert, efficient and cost-effective services to all our clients. We regularly win awards for the quality of our client service, our work and our people.

Disclaimer

This client briefing has been prepared for clients and professional associates of Ogier. The information and expressions of opinion which it contains are not intended to be a comprehensive study or to provide legal advice and should not be treated as a substitute for specific advice concerning individual situations.

Regulatory information can be found under <u>Legal Notice</u>

Meet the Author



<u>Cecilia Li</u> Partner 合伙人

Hong Kong

E: cecilia.li@ogier.com

T: <u>+852 3656 6010</u>

Key Contacts



Nathan Powell Partner 合伙人

Hong Kong

E: nathan.powell@ogier.com

T: <u>+852 3656 6054</u>



Vicky Wu

Paralegal

Hong Kong

E: vicky.wu@ogier.com

T: <u>+852 3656 6135</u>

Related Services

Equity Capital Markets

<u>Corporate</u>

<u>Legal</u>